

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Foresite Capital Management II, LLC</u> <hr/> (Last) (First) (Middle) 101 CALIFORNIA STREET SUITE 4100 <hr/> (Street) SAN FRANCISCO CA 94111 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/05/2015	3. Issuer Name and Ticker or Trading Symbol <u>Aimmune Therapeutics, Inc. [ AIMT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>	5. If Amendment, Date of Original Filed (Month/Day/Year) <hr/> 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Series B Convertible Preferred Stock	(1)	(2)	Common Stock 3,775,400	0.00	I	By: Foresite Capital Fund II, L.P. <sup>(3)</sup>

1. Name and Address of Reporting Person* <u>Foresite Capital Management II, LLC</u> <hr/> (Last) (First) (Middle) 101 CALIFORNIA STREET SUITE 4100 <hr/> (Street) SAN FRANCISCO CA 94111 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Foresite Capital Fund II, L.P.</u> <hr/> (Last) (First) (Middle) 101 CALIFORNIA STREET SUITE 4100 <hr/> (Street) SAN FRANCISCO CA 94111 <hr/> (City) (State) (Zip)		
---	--	--

1. Name and Address of Reporting Person*		
<a href="#">Tananbaum James B.</a>		
(Last)	(First)	(Middle)
<a href="#">3052 PACIFIC AVENUE</a>		
(Street)		
<a href="#">SAN FRANCISCO</a>	<a href="#">CA</a>	<a href="#">94115</a>
(City) (State) (Zip)		

**Explanation of Responses:**

- The Series B Convertible Preferred Stock automatically converts into shares of Issuer's Common Stock on a 1:1 basis immediately prior to the completion of Issuer's initial public offering.
- The expiration date is not relevant to the conversion of these securities.
- Shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the Designated Filer and general partner of FCF II, may be deemed to have the sole voting and dispositive power over the shares of Issuer's Series B Convertible Preferred Stock (the "Shares"). James Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have the sole voting and dispositive power over the Shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its partners and Mr. Tananbaum disclaims beneficial ownership of any of the Shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its partners or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.

**Remarks:**

[FORESITE CAPITAL MANAGEMENT II, LLC, By: /s/ Dennis D. Ryan, Chief Financial Officer](#) 08/05/2015

[FORESITE CAPITAL FUND II, L.P., By: Foresite Capital Management II, LLC, Its General Partner, By: /s/ Dennis D. Ryan, Chief Financial Officer](#) 08/05/2015

[/s/ James B. Tananbaum](#) 08/05/2015

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

Pursuant to General Instruction number 5(b)(v) to Form 3, the following additional reporting persons are covered by this joint filing:

Name: Foresite Capital Fund II, L.P.  
James B. Tananbaum

Address: Foresite Capital  
101 California Street  
Suite 4100  
San Francisco, CA 94111

Designated Filer: Foresite Capital Management II, LLC

Issuer and Ticker Symbol: Aimmune Therapeutics, Inc. (AIMT)

Date of Event Requiring Statement: August 5, 2015

Each of the following is a Joint Filer with Foresite Capital Management II, LLC ("FCM II") and may be deemed to share indirect beneficial ownership in the securities set forth on the attached Form 3:

FCM II is the general partner of Foresite Capital Fund II, L.P. ("FCF II"). As such, FCM II possesses sole voting and investment control over the shares owned by FCF II, and may be deemed to have indirect beneficial ownership of the securities held by FCF II, however, owns no shares of the Issuer directly. Mr. Tananbaum is the managing member of FCM II and in his capacity as such, may be deemed to exercise shared voting, investment and dispositive power over the shares held by FCF II. Each Reporting Person disclaims beneficial ownership of the shares held by FCF II except to the extent of his or its proportionate pecuniary interest therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, or otherwise, any of the Reporting Persons are the beneficial owners of all of the equity securities covered by this statement.

Each of the Reporting Persons listed above hereby designates FCM II as its designated filer of Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder.

FORESITE CAPITAL MANAGEMENT II, LLC

By: /s/ Dennis D. Ryan  
-----  
Dennis D. Ryan  
Chief Financial Officer

FORESITE CAPITAL FUND II, L.P

By: Foresite Capital Management II, LLC  
Its General Partner

By: /s/ Dennis D. Ryan  
-----  
Dennis D. Ryan  
Chief Financial Officer

/s/ James B. Tananbaum  
-----  
James B. Tananbaum